Overview

* Verastem Q2 2025 net product revenue reaches $2.1 mln post AVMAPKI FAKZYNJA launch

* Net loss for Q2 2025 widens to $25.9 mln, driven by increased expenses

* Company ends Q2 2025 with $164.3 mln cash, runway into H2 2026

Result Drivers

* AVMAPKI FAKZYNJA LAUNCH - Achieved $2.1 mln in net product revenue in first six weeks post-launch, following FDA approval for KRAS-mutated ovarian cancer treatment

* INCREASED EXPENSES - Higher R&D and administrative costs linked to clinical advancements and product launch preparations

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Net -$25.93

Income mln

Q2 Basic -$0.39

EPS

Q2 -$43.76

Income mln

from

Operatio

ns

Q2 $45.90

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Verastem Inc ( VSTM ) is $14.00, about 59.1% above its August 6 closing price of $5.72

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)